Share on LinkedInShare on LinkedIn

ARTICLE · 24 AUGUST 2016

Minsalud Will Unilaterally Set Price Of Medicine For Leukemia

Everything seemed that the declaration of the Imatinib molecule to treat cancer as a matter of public interest, would be the third case of compulsory license in Latin America, after the...

ChileIntellectual Property

Novartis says that the decision touches Intellectual Property principles in all sectors of the country.

Everything seemed that the declaration of the Imatinib molecule to treat cancer as a matter of public interest, would be the third case of compulsory license in Latin America, after the governments of Brazil and Ecuador made use of this power in the past .

Remember that in 2007 the Brazilian government granted a compulsory license for the manufacture of antiretroviral efavirenz, whose patent belongs to Merck Sharp & Dohme. Meanwhile, in 2010 the Government of Ecuador issued a compulsory license allowing the import of ritonavir antiretroviral drug manufacturer Cipla Indian pharmaceutical generic drugs whose patent holder is Abbott.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from